Mercer Global Advisors
NBIX icon

Mercer Global Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Mercer Global Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.58M Sell
56,839
-3,436
-6% -$510K 0.01% 586
2026
Q1 		$7.94M Buy
60,275
+19,318
+47% +$2.56M 0.01% 590
2025
Q4 		$5.81M Buy
40,957
+9,355
+30% +$1.36M 0.01% 668
2025
Q3 		$4.44M Buy
31,602
+17,641
+126% +$2.39M 0.01% 716
2025
Q2 		$1.75M Buy
13,961
+1,979
+17% +$227K ﹤0.01% 943
2025
Q1 		$1.33M Sell
11,982
-130
-1% -$16.5K ﹤0.01% 995
2024
Q4 		$1.65M Buy
12,112
+4,143
+52% +$512K ﹤0.01% 890
2024
Q3 		$911K Sell
7,969
-154
-2% -$21.1K ﹤0.01% 1052
2024
Q2 		$1.12M Buy
8,123
+430
+6% +$59K ﹤0.01% 925
2024
Q1 		$1.06M Buy
7,693
+2,401
+45% +$328K ﹤0.01% 937
2023
Q4 		$697K Buy
5,292
+1,219
+30% +$140K ﹤0.01% 1142
2023
Q3 		$458K Buy
4,073
+698
+21% +$73.5K ﹤0.01% 1294
2023
Q2 		$318K Buy
3,375
+121
+4% +$11.8K ﹤0.01% 1485
2023
Q1 		$329K Buy
3,254
+168
+5% +$17.5K ﹤0.01% 1453
2022
Q4 		$369K Buy
3,086
+259
+9% +$30.3K ﹤0.01% 1382
2022
Q3 		$300K Sell
2,827
-540
-16% -$54.8K ﹤0.01% 1409
2022
Q2 		$328K Buy
3,367
+430
+15% +$39.7K ﹤0.01% 1380
2022
Q1 		$275K Buy
+2,937
New +$249K ﹤0.01% 1555
2021
Q2 		– Sell
-2,960
Closed -$288K – 1717
2021
Q1 		$288K Buy
2,960
+568
+24% +$59.6K ﹤0.01% 1329
2020
Q4 		$229K Buy
+2,392
New +$231K ﹤0.01% 1176
2020
Q3 		– Sell
-1,842
Closed -$225K – 1270
2020
Q2 		$225K Buy
+1,842
New +$204K ﹤0.01% 957

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mercer Global Advisors's NBIX Position: Q2 2026 in Review

Mercer Global Advisors reduced its Neurocrine Biosciences (NBIX) stake by 5.7% in Q2 2026, selling an estimated $510K and leaving 56,839 shares worth $9.58M. The position accounts for 0.01% of the portfolio, ranked #586.

Mercer Global Advisors first reported a position in NBIX in Q2 2020 and has held it in 21 quarters since. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Mercer Global Advisors held 56,839 shares of Neurocrine Biosciences worth $9.58M as of Q2 2026.
  • Mercer Global Advisors sold 3,436 Neurocrine Biosciences shares in Q2 2026, an estimated $510K.
  • Neurocrine Biosciences made up 0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #586 holding.
  • Mercer Global Advisors first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 21 quarters since.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.